| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 23,075,261 | 5,035,006 | ||
| Other receivables | 369,157 | 188,116 | ||
| Prepaid expenses | 1,506,603 | 1,379,295 | ||
| Other current assets | 53,159 | - | ||
| Total current assets | 25,004,180 | 6,602,417 | ||
| Property and equipment, net | 1,657,255 | 1,651,656 | ||
| Operating lease right-of-use assets | 824,693 | 955,651 | ||
| Finance lease right-of-use asset | 2,244,073 | 2,699,899 | ||
| Other non-current assets | 1,018,373 | 1,069,902 | ||
| Total assets | 30,748,574 | 12,979,525 | ||
| Accounts payable | 1,844,862 | 1,762,600 | ||
| Accrued expenses | 2,324,931 | 2,523,603 | ||
| Deferred grant funding | 14,557,265 | 12,326,879 | ||
| Current portion of liability related to the sale of future royalties | 10,542 | 187,966 | ||
| Current portion of lease liabilities, operating | 609,224 | 588,478 | ||
| Current portion of lease liability, finance | 1,869,570 | 1,831,617 | ||
| Total current liabilities | 21,216,394 | 19,221,143 | ||
| Deferred revenue, non-current | 1,000,000 | 1,000,000 | ||
| Liability related to the sale of future royalties, net | 5,220,525 | 4,879,024 | ||
| Lease liabilities long-term, operating | 288,566 | 448,206 | ||
| Lease liability long-term, finance | 165,186 | 164,412 | ||
| Total liabilities | 27,890,671 | 25,712,785 | ||
| Common stock, 0.0001 par value 240,000,000 shares authorized 13,929,502 and 8,700,386 shares issued and outstanding at september30, 2025 and december31, 2024, respectively | 1,393 | 903 | ||
| Additional paid-in capital | 190,499,662 | 171,353,083 | ||
| Accumulated other comprehensive loss | -395,966 | -402,826 | ||
| Accumulated deficit | -187,247,186 | -183,684,420 | ||
| Total stockholders' equity (deficit) | 2,857,903 | -12,733,260 | ||
| Total liabilities and stockholders' equity (deficit) | 30,748,574 | 12,979,525 | ||
Dare Bioscience, Inc. (DARE)
Dare Bioscience, Inc. (DARE)